NEJM/X
Sep 30, 2025, 06:42
HI-PRO Trial: Apixaban for Long-Term Prevention of Recurrent VTE
The New England Journal of Medicine (NEJM) has shared a post on X:
“In patients with provoked venous thromboembolism and ongoing risk factors, extended treatment with low-dose apixaban for 12 months resulted in a lower risk of recurrent VTE than placebo, with a low risk of major bleeding. Full HI-PRO trial results and Research Summary.”
Title: Apixaban for Extended Treatment of Provoked Venous Thromboembolism
Authors: Gregory Piazza, Behnood Bikdeli, Arvind K. Pandey, Darsiya Krishnathasan, Candrika D. Khairani, Antoine Bejjani, Ruth H. Morrison
Read the full paper here.
Find more on Hemostasis Today.
-
Jul 2, 2026, 12:28Expanding Stroke Education Through Mobile Stroke Clinics – Ethiopia Stroke Foundation
-
Jul 2, 2026, 11:52Praveen Kumar Tirlangi: A New Mechanism of Bleeding in Kyasanur Forest Disease
-
Jul 2, 2026, 11:17Heghine Khachatryan: Novel Biomarkers for Cancer-Associated Thrombosis
-
Jul 2, 2026, 11:17Neeraj Jain: Maharashtra Is Setting the Pace for Integrated Hemoglobinopathy Care
-
Jul 2, 2026, 11:11Safaa Hilal: Improving Postpartum Hemorrhage Outcomes Through Early Warning Scores
-
Jul 2, 2026, 11:10Maria Khan Junaidi: How Age Influences Intracerebral Hemorrhage Outcomes
-
Jul 2, 2026, 10:51Faces of Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Jul 2, 2026, 10:44Priya Sriskandarajah: Understanding Anemia of Chronic Disease in Clinical Practice
-
Jul 2, 2026, 10:42Flora Peyvandi: Germline-Targeting Vaccines for HIV